XML 65 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Equity (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2023
Apr. 22, 2021
May 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2022
Nov. 09, 2022
Oct. 08, 2022
Sep. 29, 2022
Sep. 08, 2022
Mar. 26, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Number of ordinary shares granted           70,000            
Authorized number of ordinary shares [1]       1,000,000,000     1,000,000,000          
Common stock par value [1]       $ 0.025     $ 0.025          
Common stock shares issued [1]       5,100,164     3,818,663          
Number of shares issued 3,846,000                      
Purchase of ordinary shares 2,884,500                      
Net proceeds $ 4,522,314                      
Issued ordinary shares 3,846,000                      
Additional shares     12,321                  
Exercise of warrants     499,980                  
Common stock shares authorized     1,000,000,000       1,000,000,000          
Common stock shares outstanding [1]       5,100,164     3,818,663          
Paid-in-capital, registered capital and statutory reserves       $ 19,800,000     $ 19,300,000          
Statutory reserves       $ 449,136     $ 449,136          
IPO [Member]                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Number of warrant purchase   125,000   125,000                
Share price   $ 20.00   $ 20.00                
Expiration date   Mar. 31, 2026                    
Warrant remaining lives       2 years 9 months                
Securities Purchase Agreement 1 [Member]                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Common stock shares issued                   500,000    
Sale of common stock                   500,000    
Consideration amount                   $ 277,500    
Securities Purchase Agreement 2 [Member]                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Common stock shares issued                 500,000      
Sale of common stock                 500,000      
Consideration amount                 $ 287,500      
Securities Purchase Agreement 3 [Member]                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Common stock shares issued               500,000        
Sale of common stock               500,000        
Consideration amount               $ 202,500        
Common Stock [Member]                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Authorized number of ordinary shares                     50,000,000  
Common stock par value                     $ 0.001  
Common stock shares issued                       19,000,000
Two Consulting Firms [Member]                        
Accumulated Other Comprehensive Income (Loss) [Line Items]                        
Number of ordinary shares granted           70,000            
Grant date fair value           $ 150,600            
Share based compensation       $ 0 $ 10,134              
[1] retroactively restated to reflect 1-for-5 share consolidation effective on September 9, 2022 and 1-for-5 share consolidation effective on May 15, 2023.